Tratamento da síndrome do intestino irritável tipo diarreia-predominante com mesalazina e/ou saccharomyces boulardii
| Autor: | Joffre Resende-Filho, Enio Chaves de Oliveira, Naylé V. Leite, Mauro Bafutto, Jose R. Almeida, Michelle B. Costa |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male Diarrhea medicine.medical_specialty Abdominal pain Síndrome do intestino irritável Sindrome do intestino irritavel Colonoscopy Gastroenterology law.invention Irritable Bowel Syndrome Saccharomyces chemistry.chemical_compound Probiotic Pharmacotherapy Mesalazine law Internal medicine medicine Humans Mesalamina Diarreia lcsh:RC799-869 Mesalamine Irritable bowel syndrome biology medicine.diagnostic_test business.industry Probiotics Anti-Inflammatory Agents Non-Steroidal Middle Aged medicine.disease biology.organism_classification Saccharomyces boulardii Treatment Outcome chemistry Drug Therapy Combination Female lcsh:Diseases of the digestive system. Gastroenterology medicine.symptom business |
| Zdroj: | Arquivos de Gastroenterologia, Vol 50, Iss 4, Pp 304-309 (2013) Arquivos de Gastroenterologia v.50 n.4 2013 Arquivos de gastroenterologia Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia instacron:IBEPEGE Arquivos de Gastroenterologia, Volume: 50, Issue: 4, Pages: 304-309, Published: DEC 2013 |
| ISSN: | 0004-2803 |
| Popis: | ContextIrritable bowel syndrome (IBS) is a functional bowel disease characterized by abdominal pain and altered intestinal habits. The pathophysiology of IBS remains unclear. Recent studies have demonstrated that some IBS patients, especially in diarrhea-predominant IBS (IBS-D), display persistent signs of minor mucosal inflammation and a modified intestinal microflora. The mesalazine has known intestinal anti-inflammatory properties. Saccharomyces boulardii is a probiotic used for a long time in treatment of diarrhea, including infectious diarrhea.ObjectiveEvaluate the effects of mesalazine alone, combined therapy of mesalazine with liophylised Saccharomyces boulardii or alone on symptoms of IBS-D patients.MethodsBased on Rome III criteria, 53 IBS-D patients (18 year or more) were included. To exclude organic diseases all patients underwent colonoscopy, stool culture, serum anti-endomisium antibody, lactose tolerance test and ova and parasite exam. Patients were divided in three groups: mesalazine group (MG) - 20 patients received mesalazine 800 mg t.i.d. for 30 days; mesalazine and Saccharomyces boulardii group (MSbG) - 21 patients received mesalazine 800 mg t.i.d. and Saccharomyces boulardii 200 mg t.i.d. for 30 days and; Saccharomyces boulardii group (SbG) – 12 patients received Sb 200 mg t.i.d. for 30 days. Drugs that might have any effect on intestinal motility or secretion were not allowed. Symptom evaluations at baseline and after treatment were performed by means of a 4-point likert scale including: stool frequency, stool form and consistency (Bristol scale), abdominal pain and distension. Paired t test and Kruskal-Wallis test were used for statistical analyses.ResultsCompared to baseline, there were statistically significant reduction of symptom score after 30 th day therapy in all three groups: MG (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|